Enhanced Wound Healing for Diabetics

促进糖尿病患者的伤口愈合

• 批准号: 6484343
• 负责人: JEFFREY A GREENSPAN
• 金额: $ 46.94万
• 依托单位: MUNIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6484343
• 关键词: angiogenesis; antiserum; biomarker; collagen; diabetes mellitus; drug screening /evaluation; growth factor; immediate early protein; laboratory mouse; nonhuman therapy evaluation; protein purification; recombinant proteins; skin; topical drug application; wound healing

Description (provided by applicant): Impaired and delayed wound healing are significant problems in diabetics. Furthermore, aging and diabetes together further compound the problem. These observations have created interest in pharmacologic enhancement of healing with growth factors involved in the body?s wound repair process. Clinical trials have been discouraging, with only modest improvement in wound repair in humans. Studies indicate that cells in healing-impaired individuals may fail to respond adequately to growth factors. Thus, wound healing in such individuals may not be improved by growth factor treatment, but may require administration of downstream factors normally induced in cells in response to growth factors involved in healing, but not induced in cells of those with poor wound healing capability. In Phase I of this proposal, a particular factor that is strongly implicated as a critical component of wound healing in the body, and whose expression is normally induced by growth factors, will be tested for its ability to enhance wound healing in diabetic mice. If successful, this factor will be developed in Phase II as a clinical wound-healing agent, particularly for those with impaired wound healing, such as diabetics. PROPOSED COMMERCIAL APPLICATION: Wound treatment costs total billions of dollars (almost $10 billion for pressure ulcers alone). Impaired and delayed wound healing affect more than a half million individuals annually and are significant problems in diabetics (over 15 million diabetics are in the U.S.) and the elderly. Impaired/delayed healing also has severe impact on ischemia that leads to heart attacks (the leading cause of mortality) and limb amputations.

描述（由申请人提供）：伤口愈合受损和延迟是糖尿病患者的重要问题。此外，衰老和糖尿病一起进一步加剧了这个问题。这些观察结果产生了兴趣，在药理学增强愈合与生长因子参与身体？的伤口修复过程。临床试验一直令人沮丧，在人类伤口修复方面只有适度的改善。研究表明，愈合受损个体的细胞可能无法充分响应生长因子。因此，这些个体的伤口愈合可能不能通过生长因子治疗来改善，但可能需要施用下游因子，所述下游因子通常在细胞中响应于参与愈合的生长因子而诱导，但在伤口愈合能力差的那些细胞中不诱导。在该提案的第一阶段，将测试一种特定因子增强糖尿病小鼠伤口愈合的能力，该因子强烈暗示为体内伤口愈合的关键组分，并且其表达通常由生长因子诱导。如果成功，这种因子将在第二阶段开发为临床伤口愈合剂，特别是对于那些受损的人。 伤口愈合，如糖尿病。 拟议的商业应用：伤口治疗费用总计数十亿美元（仅压疮就近100亿美元）。伤口愈合受损和延迟每年影响超过50万人，并且是糖尿病患者的重要问题（在美国超过1500万糖尿病患者）。和老年人。 受损/延迟愈合也对缺血有严重影响，导致心脏病发作（死亡的主要原因）和截肢。